Biotech Values

[DewDiligence]

ACHN:

…presumably that means disseminating top-line data at the JPM conference in January. Management did issue a caveat that there could be a slight delay if they decide to add an additional cohort to the Phase 1b trial. I didn't get the impression that they actually intended to do this additional cohort though.

If the results are good, I think ACHN will find a way to release the top-line data at the JPM conference—even if they do decide to run another dosing cohort. The corollary is that not releasing at least some top-line data at JPM ought to be interpreted as a negative signal.